MCID: SCH003
MIFTS: 43

Schizophreniform Disorder

Categories: Mental diseases

Aliases & Classifications for Schizophreniform Disorder

MalaCards integrated aliases for Schizophreniform Disorder:

Name: Schizophreniform Disorder 12 77 15
Schizophreniform Disorders 56 74
Psychotic Disorders 45 74

Classifications:



External Ids:

Disease Ontology 12 DOID:11328
ICD9CM 36 295.4
MeSH 45 D011618
NCIt 51 C94376
SNOMED-CT 69 88975006
ICD10 34 F20.81

Summaries for Schizophreniform Disorder

Disease Ontology : 12 A psychotic disorder that involves schizophrenia symptoms over time period of one month.

MalaCards based summary : Schizophreniform Disorder, also known as schizophreniform disorders, is related to schizoaffective disorder and traumatic brain injury, and has symptoms including photophobia, restlessness and personality changes. An important gene associated with Schizophreniform Disorder is PRL (Prolactin), and among its related pathways/superpathways is Signaling by ERBB4. The drugs Dopamine and Amisulpride have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and bone.

Wikipedia : 77 Schizophreniform disorder is a mental disorder diagnosed when symptoms of schizophrenia are present for... more...

Related Diseases for Schizophreniform Disorder

Diseases related to Schizophreniform Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 137)
# Related Disease Score Top Affiliating Genes
1 schizoaffective disorder 32.0 COMT DRD2 PRL
2 traumatic brain injury 30.4 COMT DRD2
3 brain injury 30.4 COMT DRD2
4 substance abuse 30.2 COMT DRD2 PRL
5 hyperprolactinemia 30.0 DRD2 PRL
6 post-traumatic stress disorder 29.9 COMT DRD2
7 schizophrenia 29.9 COMT DRD2 GRM3 NRG1 PRL
8 obsessive-compulsive disorder 29.8 COMT DRD2 PRL
9 cannabis dependence 29.8 COMT NRG1
10 personality disorder 29.8 COMT DRD2 PRL
11 alexithymia 29.7 COMT DRD2
12 pituitary adenoma, prolactin-secreting 29.7 DRD2 PRL
13 bipolar disorder 29.7 COMT DRD2 NRG1
14 bipolar i disorder 29.7 COMT NRG1
15 major depressive disorder 29.7 COMT DRD2 PRL
16 alcohol abuse 29.7 DRD2 PRL
17 mood disorder 29.7 COMT DRD2
18 disease of mental health 29.5 COMT DRD2 NRG1 SLC27A5
19 psychotic disorder 29.4 COMT DRD2 NRG1 PRL
20 drug psychosis 11.2
21 mental retardation, x-linked, syndromic 13 11.0
22 schizophrenia 4 11.0
23 schizophrenia 2 11.0
24 schizophrenia 9 11.0
25 schizophrenia 15 11.0
26 chromosome 2p16.3 deletion syndrome 11.0
27 schizophrenia 18 11.0
28 schizophrenia 19 11.0
29 galactorrhea 10.2 DRD2 PRL
30 prolactin producing pituitary tumor 10.2 DRD2 PRL
31 social phobia 10.2 DRD2 PRL
32 peripartum cardiomyopathy 10.2 DRD2 PRL
33 functioning pituitary adenoma 10.2 DRD2 PRL
34 mammographic density 10.2 COMT PRL
35 migraine without aura 10.1 DRD2 PRL
36 cocaine abuse 10.1 DRD2 PRL
37 polysubstance abuse 10.1 COMT DRD2
38 fibromyalgia 10.1 COMT PRL
39 tardive dyskinesia 10.1 COMT DRD2
40 postpartum depression 10.1 COMT PRL
41 depression 10.1
42 epilepsy 10.1
43 oppositional defiant disorder 10.1 COMT DRD2
44 opioid addiction 10.1 COMT DRD2
45 antisocial personality disorder 10.1 COMT DRD2
46 conduct disorder 10.0 COMT DRD2
47 generalized anxiety disorder 10.0 COMT DRD2
48 autism 10.0
49 encephalopathy 10.0
50 eating disorder 10.0 COMT DRD2

Comorbidity relations with Schizophreniform Disorder via Phenotypic Disease Network (PDN): (show top 50) (show all 118)


Active Peptic Ulcer Disease Acute Conjunctivitis
Acute Cystitis Acute Kidney Failure
Acute Myocardial Infarction Adjustment Disorder
Age-Related Hearing Loss Alcohol Abuse
Alzheimer Disease Amnestic Disorder
Antisocial Personality Disorder Anxiety
Aortic Valve Disease 1 Atypical Depressive Disorder
Bacteremia 2 Bipolar Disorder
Blepharitis Borderline Personality Disorder
Brain Cancer Bronchitis
Bronchopneumonia Bullous Pemphigoid
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Chronic Kidney Failure
Chronic Myocardial Ischemia Chronic Ulcer of Skin
Communicating Hydrocephalus Conduct Disorder
Conjunctivitis Conversion Disorder
Cyclothymic Disorder Cystitis
Decubitus Ulcer Deficiency Anemia
Delusional Disorder Dependent Personality Disorder
Dermatomycosis Diabetes Mellitus, Noninsulin-Dependent
Dysthymic Disorder Encephalopathy
Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation Erythematosquamous Dermatosis
Esophageal Disease Esophagitis
Familial Atrial Fibrillation Fecal Incontinence
Folic Acid Deficiency Anemia Generalized Anxiety Disorder

Graphical network of the top 20 diseases related to Schizophreniform Disorder:



Diseases related to Schizophreniform Disorder

Symptoms & Phenotypes for Schizophreniform Disorder

UMLS symptoms related to Schizophreniform Disorder:


photophobia, restlessness, personality changes, pseudobulbar behavioral symptoms, sleep disturbances, mental and behavioral signs and symptoms, clouded consciousness, catatonic reaction

Drugs & Therapeutics for Schizophreniform Disorder

Drugs for Schizophreniform Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 191)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
2
Amisulpride Approved, Investigational Phase 4,Not Applicable 71675-85-9, 53583-79-2 2159
3
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
4
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
5
Risperidone Approved, Investigational Phase 4,Phase 3,Not Applicable 106266-06-2 5073
6
Donepezil Approved Phase 4 120014-06-4 3152
7
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
8
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
9
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
10
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
11
Clozapine Approved Phase 4,Phase 1 5786-21-0 2818
12
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 132539-06-1 4585
13
Citalopram Approved Phase 4 59729-33-8 2771
14
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
15
Pravastatin Approved Phase 4 81093-37-0 54687
16
Molindone Approved Phase 4 7416-34-4 23897
17
Metformin Approved Phase 4 657-24-9 14219 4091
18
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
19
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
20 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Antidepressive Agents Phase 4,Phase 3,Not Applicable
22 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Antidepressive Agents, Second-Generation Phase 4,Not Applicable
24 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Central Nervous System Stimulants Phase 4,Not Applicable
30 Cytochrome P-450 CYP3A Inducers Phase 4
31 Serotonin 5-HT2 Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1
32 Wakefulness-Promoting Agents Phase 4
33 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Dopamine agonists Phase 4,Phase 3
36 Dopamine D2 Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1
37 Serotonin 5-HT1 Receptor Agonists Phase 4,Phase 3
38 Serotonin Receptor Agonists Phase 4,Phase 3
39 Cholinergic Agents Phase 4,Not Applicable
40 Cholinesterase Inhibitors Phase 4
41 Nootropic Agents Phase 4
42 glucocorticoids Phase 4
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
44 Protective Agents Phase 4,Phase 2,Phase 3,Not Applicable
45 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Neuroprotective Agents Phase 4
47 Antineoplastic Agents, Hormonal Phase 4
48 Hormone Antagonists Phase 4,Phase 3,Phase 2
49 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Methylprednisolone Acetate Phase 4

Interventional clinical trials:

(show top 50) (show all 113)
# Name Status NCT ID Phase Drugs
1 Association of Amisulpride Response in Schizophrenia With Brain Image Unknown status NCT02095938 Phase 4 amisulpride
2 Antipsychotic Effects on Brain Function in Schizophrenia Unknown status NCT01913327 Phase 4 Aripiprazole;Risperidone;Modafinil
3 Donepezil Double Blind Trial for ECT Memory Disfunction Unknown status NCT00465283 Phase 4 Donepezil
4 Prednisolone Addition for Patients With Recent-onset Psychotic Disorder Unknown status NCT02949232 Phase 4 Prednisolone;Placebo Oral Tablet
5 The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder Completed NCT00044187 Phase 4 Sibutramine
6 Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia Completed NCT02137993 Phase 4 A-prexa;Zyprexa
7 Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS) Completed NCT00304655 Phase 4 Aripiprazole
8 Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia Completed NCT00485823 Phase 4 Olanzapine Hydrochloride
9 DECIFER: Depression and Citalopram In First Episode Recovery Completed NCT01041274 Phase 4 Citalopram;Placebo
10 An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders Completed NCT01855074 Phase 4 Risperidone
11 Varenicline Adjunctive Treatment in Schizophrenia Completed NCT00492349 Phase 4 Varenicline;Placebo
12 Optimization of Treatment and Management of Schizophrenia in Europe Completed NCT01248195 Phase 4 Amisulpride open label;6-week amisulpride double blind treatment;6-week olanzapine double blind treatment;12-week clozapine open-label treatment
13 A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis Completed NCT00246259 Phase 4 Risperidone long-acting injection (LAI);Oral Antipsychotic
14 Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia Completed NCT00103571 Phase 4 Olanzapine;Aripiprazole
15 Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset Schizophrenia Completed NCT00847600 Phase 4
16 Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia Completed NCT01082588 Phase 4 Pravastatin;Placebo
17 Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS) Completed NCT00053703 Phase 4 Risperidone;Olanzapine (enrollment closed in this treatment);Molindone
18 Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia Completed NCT00595504 Phase 4 Ramelteon;Placebo
19 Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia Completed NCT00361543 Phase 4 Raloxifene hydrochloride
20 Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia Completed NCT00337662 Phase 4 olanzapine;risperidone;risperidone
21 Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia Completed NCT00330551 Phase 4 Oral Risperidone;Risperidone in Long-Acting Injectable Form (Consta)
22 An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications. Completed NCT00391261 Phase 4 Metformin
23 Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia Completed NCT00333177 Phase 4 Risperidone, administered orally;Risperidone, administered via injection
24 Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis Completed NCT00320671 Phase 4 Aripiprazole;Risperidone
25 Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men? Recruiting NCT01481883 Phase 4 Raloxifene Hydrochloride;Placebo
26 Research Into Antipsychotic Discontinuation and Reduction Trial Recruiting NCT03559426 Phase 4 Antipsychotic Reduction;Antipsychotic Maintenance
27 Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia Recruiting NCT01451736 Phase 4 paliperidone palmitate;risperidone
28 Schizophrenic Patients in Integrated Care Terminated NCT00681629 Phase 4 Quetiapine XR
29 Optimizing Response in Psychosis Study Terminated NCT00314327 Phase 4 long-acting injectable risperidone
30 Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia Withdrawn NCT03061136 Phase 4 Clonazepam;Placebo
31 Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia Unknown status NCT01121042 Phase 3 Ondansetron;Placebo
32 Estradiol Patch as add-on to Antipsychotics in Patients With Schizophrenia, Schizoaffective or Schizophreniform Disorder Completed NCT03848234 Phase 3 Estradiol
33 Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients Completed NCT00159770 Phase 3 ziprasidone versus olanzapine , risperidone or quetiapine
34 Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study Completed NCT00145444 Phase 3 olanzapine;ziprasidone
35 CAFE Comparison of Atypicals in First Episode of Psychosis Completed NCT00034892 Phase 3 Olanzapine, risperidone
36 Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants Completed NCT00419146 Phase 2, Phase 3 Ethyl-eicosapentaenoic acid (EPA);Vitamins E + C
37 Open-label Ziprasidone Study for Psychosis Treatment in Adolescents Completed NCT00421954 Phase 3 Ziprasidone
38 A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis Completed NCT00216580 Phase 3 Risperidone, long-acting injectable
39 Simvastatin Addition for Patients With Recent-onset Schizophrenia Recruiting NCT01999309 Phase 3 Simvastatin;Placebo
40 Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder Recruiting NCT03187769 Phase 3 ALKS 3831;Olanzapine
41 Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder Recruiting NCT03043820 Phase 3 Raloxifene;Placebo
42 A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform Active, not recruiting NCT02431702 Phase 3 Aripiprazole;Haloperidol;Olanzapine;Oral Paliperidone ER;Perphenazine;Quetiapine;Oral Risperidone;Paliperidone Palmitate Injection (PP1M);Paliperidone Palmitate Injection (PP3M)
43 Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 Enrolling by invitation NCT03201757 Phase 3 ALKS 3831
44 Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset Psychosis Unknown status NCT00465920 Phase 2
45 A Definitive Estrogen Patch Study (ADEPT) Completed NCT00357006 Phase 2 Estradiol;Estradiol
46 Effectiveness of Adherence Therapy for Schizophrenia Completed NCT01780116 Phase 1, Phase 2
47 Clinical Estradiol Trial in Women With Schizophrenia Completed NCT00206570 Phase 2 Estradiol
48 The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study Completed NCT00206557 Phase 2 Raloxifene;Estradiol/dyhydroprogestrone
49 Randomized Double Blind Placebo Control Study in Patients With Schizophrenia Completed NCT01602029 Phase 2 Ondansetron;Simvastatin;Placebo;Odansetron plus simvastatin
50 Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents Completed NCT01731119 Phase 2 Latuda©

Search NIH Clinical Center for Schizophreniform Disorder

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: psychotic disorders

Genetic Tests for Schizophreniform Disorder

Anatomical Context for Schizophreniform Disorder

MalaCards organs/tissues related to Schizophreniform Disorder:

42
Brain, Testes, Bone, Spinal Cord, Thyroid

Publications for Schizophreniform Disorder

Articles related to Schizophreniform Disorder:

(show top 50) (show all 97)
# Title Authors Year
1
Effects of socio-demographic characteristics, premorbid functioning, and insight on duration of untreated psychosis in first-episode schizophrenia or schizophreniform disorder in Northern Malawi. ( 30706661 )
2019
2
Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. ( 30115598 )
2018
3
Baseline Demographics and Characteristics From a Paliperidone Palmitate Study in Subjects with Recent-Onset Schizophrenia or Schizophreniform Disorder. ( 28839335 )
2017
4
Hypocalcemia Masquerading as Schizophreniform Disorder. ( 27833232 )
2016
5
White matter alterations associated with suicide in patients with schizophrenia or schizophreniform disorder. ( 26774424 )
2016
6
Similarities in early course among men and women with a first episode of schizophrenia and schizophreniform disorder. ( 21614663 )
2012
7
Treatment of schizophreniform disorder by aripiprazole in a female adolescent with 22q11.2 deletion syndrome. ( 20493229 )
2010
8
Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study. ( 19154213 )
2009
9
Hypothermia and rhabdomyolysis following olanzapine injection in an adolescent with schizophreniform disorder. ( 19555799 )
2009
10
Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). ( 19369319 )
2009
11
Effects of a neuregulin 1 variant on conversion to schizophrenia and schizophreniform disorder in people at high risk for psychosis. ( 19156152 )
2009
12
Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). ( 19819114 )
2009
13
Specific brain structural abnormalities in first-episode schizophrenia. A comparative study with patients with schizophreniform disorder, non-schizophrenic non-affective psychoses and healthy volunteers. ( 19796919 )
2009
14
Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. ( 18312044 )
2008
15
Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response. ( 18280582 )
2008
16
Schizophreniform disorder after heat injury in a military recruit. ( 18621941 )
2008
17
Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder. ( 18053652 )
2008
18
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. ( 18374841 )
2008
19
Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. ( 17854239 )
2007
20
Predictors of the evolution towards schizophrenia or mood disorder in patients with schizophreniform disorder. ( 17851043 )
2007
21
Chromosomal translocation t(1;4) (p21;p14) indicating possible susceptibility loci for schizophreniform disorder and mental retardation. ( 17827423 )
2007
22
Neuropsychological performance at the age of 13 years and adult schizophreniform disorder: prospective birth cohort study. ( 17077440 )
2006
23
Improvement of psychiatric symptoms after electroconvulsive therapy in young adults with intractable first-episode schizophrenia and schizophreniform disorder. ( 17077598 )
2006
24
Supportive psychotherapy for a patient with psychosis: schizophreniform disorder. ( 21103151 )
2006
25
Early insight predicts depression and attempted suicide after 4 years in first-episode schizophrenia and schizophreniform disorder. ( 16279874 )
2005
26
Patients with schizophreniform disorder use verbal descriptions for the representation of visual categories. ( 14982130 )
2004
27
Cotard's syndrome with schizophreniform disorder can be successfully treated with electroconvulsive therapy: case report. ( 15069468 )
2004
28
A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder. ( 15206670 )
2004
29
Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. ( 15231551 )
2004
30
Outcome of schizophreniform disorder. ( 12773271 )
2003
31
Persistent early childhood developmental impairment may be associated with later schizophreniform disorder. ( 12588823 )
2003
32
Schizophreniform disorder with cerebrospinal fluid PCR positivity for herpes simplex virus type 1. ( 14530627 )
2003
33
Childhood origins of violent behaviour in adults with schizophreniform disorder. ( 14645023 )
2003
34
Distinguishing between first-admission schizophreniform disorder and schizophrenia. ( 12765743 )
2003
35
Exploration of dimensions of psychopathology in neuroleptic-naA^ve patients with recent-onset schizophrenia/schizophreniform disorder. ( 14572620 )
2003
36
Working memory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder. ( 12611829 )
2003
37
A follow-up study of patients with DSM-IV schizophreniform disorder. ( 11873709 )
2002
38
Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. ( 11982449 )
2002
39
The effects of neuroleptic medications on basal ganglia blood flow in schizophreniform disorders: a comparison between the neuroleptic-naïve and medicated states. ( 12399138 )
2002
40
Treatment of a biracial child with schizophreniform disorder: cultural formulation. ( 10975171 )
2000
41
Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. ( 11074871 )
2000
42
First-episode schizophreniform disorder: comparisons with first-episode schizophrenia. ( 11099883 )
2000
43
Induction of a schizophreniform disorder by a spinal cord stimulator. ( 9989125 )
1999
44
Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder. ( 10584762 )
1999
45
Schizophreniform disorder: exception proves the rule. ( 10360149 )
1999
46
Spontaneous abnormal involuntary movements in first-episode schizophrenia and schizophreniform disorder: baseline rate in a group of patients from an Irish catchment area. ( 9734543 )
1998
47
DSM-III-R schizophreniform disorder with good prognostic features: a six-year follow-up. ( 9533972 )
1998
48
Oculo-auriculo-vertebral spectrum disorder (Goldenhar "syndrome") coexisting with schizophreniform disorder. ( 9667580 )
1998
49
Family history of DSM-III-R schizophreniform disorder with good prognostic features. ( 9653543 )
1998
50
Comorbidity of schizophreniform disorder and borderline personality disorder in an 18-year-old black woman. ( 9521370 )
1998

Variations for Schizophreniform Disorder

Expression for Schizophreniform Disorder

Search GEO for disease gene expression data for Schizophreniform Disorder.

Pathways for Schizophreniform Disorder

Pathways related to Schizophreniform Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.66 NRG1 PRL

GO Terms for Schizophreniform Disorder

Cellular components related to Schizophreniform Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.71 DRD2 GRM3 NRG1 SEMA3C
2 glutamatergic synapse GO:0098978 9.43 DRD2 GRM3 NRG1
3 GABA-ergic synapse GO:0098982 9.37 DRD2 NRG1
4 integral component of presynaptic membrane GO:0099056 9.32 DRD2 GRM3
5 integral component of postsynaptic membrane GO:0099055 9.16 DRD2 GRM3
6 dendritic spine GO:0043197 9.13 COMT DRD2 GRM3
7 axon GO:0030424 8.92 COMT DRD2 GRM3 NRG1

Biological processes related to Schizophreniform Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 female pregnancy GO:0007565 9.37 COMT PRL
2 locomotory behavior GO:0007626 9.32 DRD2 NRG1
3 synapse assembly GO:0007416 9.26 DRD2 NRG1
4 mammary gland development GO:0030879 9.16 NRG1 PRL
5 dopamine metabolic process GO:0042417 8.96 COMT DRD2
6 response to drug GO:0042493 8.8 COMT DRD2 SEMA3C

Molecular functions related to Schizophreniform Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemorepellent activity GO:0045499 8.62 NRG1 SEMA3C

Sources for Schizophreniform Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....